Off-label use of atypical antipsychotics: an update


Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
Antipsychotic medications are approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia, bipolar disorder, and for some drugs, depression. We performed a systematic review on the efficacy and safety of atypical antipsychotic drugs for use in conditions lacking FDA approval.

Authors' conclusions
Benefits and harms vary among atypical antipsychotics for off-label usage. For symptoms associated with dementia in elderly patients, small but statistically significant benefits were observed for aripiprazole, olanzapine, and risperidone. Quetiapine was associated with benefits in the treatment of generalized anxiety disorder, and risperidone was associated with benefits in the treatment of OCD; however, adverse events were common.

Project page URL

Final publication URL
http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=778&PCem=EGD

URL for DARE abstract
http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12011005876

Indexing Status
Subject indexing assigned by CRD

MeSH
Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Dementia; Depressive Disorder, Major; Feeding and Eating Disorders; Obsessive-Compulsive Disorder; Off-Label Use; Personality Disorders; Schizophrenia; Sleep Initiation and Maintenance Disorders; Stress Disorders, Post-Traumatic; Substance-Related Disorders; Tourette Syndrome

Language Published
English

Country of organisation
United States

Address for correspondence
AHRQ, Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA Email: AHRQ-TAP@ahrq.hhs.gov